Neurogene (NGNE) EPS (Weighted Average and Diluted) (2017 - 2026)
Neurogene (NGNE) reported EPS (Weighted Average and Diluted) of -$1.39 for Q1 2026, down 28.7% on a YoY basis from -$1.95 in Q1 2025, and down 23.01% quarter-over-quarter from -$1.13 in Q4 2025.
Neurogene (NGNE) EPS (Weighted Average and Diluted) (2017 - 2026) Analysis & Trends
Neurogene has reported EPS (Weighted Average and Diluted) for 10 years, with the latest figure at -$1.39 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 28.7% year-over-year to -$1.39; the trailing twelve-month figure through Mar 2026 stood at -$4.56 (down 4.83% YoY), and the FY2025 full-year result was -$4.24, up 0.93% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$1.39, down from -$1.13 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $3.99 in Q4 2022, with the low at -$32.67 in Q3 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$4.0 across 5 years, with a median of -$1.06 in 2025.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) soared 1577.78% — and 2023, when it tumbled 9428.57%.
- Neurogene's EPS (Weighted Average and Diluted) stood at $3.99 in 2022, then declined by 26.57% to $2.93 in 2023, then slumped by 133.79% to -$0.99 in 2024, then decreased by 14.14% to -$1.13 in 2025, then retreated by 23.01% to -$1.39 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.39 (Q1 2026), -$1.13 (Q4 2025), and -$0.99 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | -1.39 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.39 |
| Dec 31, 2025 | -1.13 |
| Sep 30, 2025 | -0.99 |
| Jun 30, 2025 | -1.05 |
| Mar 31, 2025 | -1.08 |
| Dec 31, 2024 | -0.99 |
| Sep 30, 2024 | -1.19 |
| Jun 30, 2024 | -1.09 |
| Mar 31, 2024 | -1.00 |
| Dec 31, 2023 | 2.93 |
| Sep 30, 2023 | -32.67 |
| Jun 30, 2023 | -26.68 |
| Dec 31, 2022 | 3.99 |
| Sep 30, 2022 | -1.18 |
| Jun 30, 2022 | -0.28 |
| Mar 31, 2022 | -0.28 |
| Dec 31, 2021 | -0.27 |
| Sep 30, 2021 | -0.28 |
| Jun 30, 2021 | -0.27 |
| Mar 31, 2021 | -0.27 |